Vanda Pharmaceuticals opened lower at $4.13, compared with its previous close of $4.15. In the last trading session, the stock traded between $3.94 and $4.18. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Vanda Pharmaceuticals is now worth
$ 21.77
Resulting in a loss of
$ 78.23 (78.23%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.20 (-4.80%)
Day High
$4.18
Day Low
$3.94
Day Open
$4.13
Prev Close
$4.15
Volume
10,03,222
1W Return
1.99%
1M Return
-12.88%
3M Return
-19.61%
6M Return
-36.99%
1Y Return
-9.79%
Market Cap ($ Mn)
239
PE Ratio
-
PB Ratio
1.45
PEG Ratio
-
ROE
-47.32%
ROCE
-28.71%
EPS (TTM)
$-0.37
1 Week
1.99%
1 Month
-12.88%
3 Months
-19.61%
6 Months
-36.99%
9 Months
-46.82%
Vanda Pharmaceuticals to report Q3 2026 results on Oct 28
Vanda Pharmaceuticals Inc. will announce Q3 2026 results on October 28, 2026. Conference call scheduled for 4:30 pm ET with management discussion. Replay available from October 28 at 8:30 pm ET until November 4, 2026.
22 days agoVanda Pharmaceuticals VQW-765 fails Phase III social anxiety trial
Vanda Pharmaceuticals' Phase III study of VQW-765 missed its primary endpoint. The drug failed to show efficacy in treating acute social anxiety disorder. VQW-765 remained safe and well tolerated throughout the trial. Results are consistent with prior studies regarding the drug's safety profile.
29 days agoVanda Pharmaceuticals reports positive Phase 3 results for HETLIOZ in DSWPD
Vanda Pharmaceuticals reported positive Phase 3 topline results for HETLIOZ in adults with Delayed Sleep-Wake Phase Disorder. The trial showed a statistically significant 37.1-minute difference in sleep onset advancement compared to placebo. 60% of tasimelteon participants advanced sleep timing by at least 30 minutes versus 15% on placebo. The company plans to submit a supplemental New Drug Application to the FDA seeking full regulatory approval. If approved, HETLIOZ would become the first FDA-cleared medication designated for this specific circadian condition.
1mo agoVanda Pharmaceuticals secures EU orphan designation for imsidolimab
Vanda Pharmaceuticals received EU orphan designation for imsidolimab. Drug treats generalized pustular psoriasis (GPP) in rare cases. Follows similar approvals from US FDA and Japan's MHLW. FDA BLA review ongoing with target date of December 12, 2026. Benefits include reduced fees and market exclusivity in EU.
2mo agoVanda Pharmaceuticals Q2 Results: Earnings Date Set for Aug 5
Vanda Pharmaceuticals Inc. set August 5, 2026, as the date for its second quarter 2026 earnings release. A management-led conference call will follow at 4:30 PM ET, with replays available until August 12, 2026.
3mo agoEMA grants orphan designation to Vanda's Imsidolimab for GPP
Vanda Pharmaceuticals Inc. received a positive opinion from the EMA for orphan drug designation of imsidolimab to treat generalized pustular psoriasis (GPP), marking the first such recognition in the EU. The drug inhibits IL-36 receptor signaling to address a deficiency in patients with this rare, life-threatening disease. The designation offers incentives like protocol assistance and market exclusivity, while the FDA is reviewing the BLA with a target action date of December 12, 2026.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Vanda Pharmaceuticals is now worth
$ 21.77
Resulting in a loss of
$ 78.23 (78.23%)
Note: Past profits do not guarantee future returns.
